Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 2/2012

01-06-2012 | Methods and Clinical Tools for Outcome Assessments

Refining endpoints in brain tumor clinical trials

Authors: Christina A. Meyers, Edwin P. Rock, Howard A. Fine

Published in: Journal of Neuro-Oncology | Issue 2/2012

Login to get access

Abstract

As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.
Literature
1.
Meyers CA, Hess KR, Yung WKA, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646–650PubMed
2.
Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5:89–95PubMed
3.
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1943–1972
4.
O’Shaughnessy JA, Wittes RE, Burke G et al (1991) Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9:2225–2232PubMed
5.
Brown PD, Jensen AW, Felton SJ et al (2006) Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 24:5427–5433PubMedCrossRef
6.
Wefel JS, Cloughsey TF, Zazzali JL et al (2011) Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:660–668PubMedCrossRef
7.
Meyers CA, Brown PD (2006) The role and relevance of neurocognitive assessment in clinical trials of patients with central nervous system tumors. J Clin Oncol 24:1305–1309PubMedCrossRef
8.
Meyers CA, Wefel JS (2003) The use of the Mini Mental State Examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557–3558PubMedCrossRef
9.
Meyers CA, Smith JA, Bezjak A et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165PubMedCrossRef
10.
Wolfson AH, Bae K, Komaki R et al (2011) Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81:77–84PubMedCrossRef
11.
Correa DD, Maron L, Harder H et al (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18:1145–1151PubMedCrossRef
12.
Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708PubMedCrossRef
13.
Benedict RHB, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test–Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43–55CrossRef
14.
Benton AL, KdeS Hamsher (1989) Multilingual aphasia examination. AJA Associates, Iowa City
15.
Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment. Oxford University Press, New York
Metadata
Title
Refining endpoints in brain tumor clinical trials
Authors
Christina A. Meyers
Edwin P. Rock
Howard A. Fine
Publication date
01-06-2012
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-012-0813-8

Other articles of this Issue 2/2012

Journal of Neuro-Oncology 2/2012 Go to the issue

Baseline Neuropsychological Investigations and Batteries

Pre- and post-operative assessment of visuo-spatial functions in right hemisphere tumour patients: a pilot study

Effects of Standard of Art Treatment

Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery

Methods and Clinical Tools for Outcome Assessments

Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies

Effects of Standard of Art Treatment

Cognitive outcome after awake surgery for tumors in language areas

Baseline Neuropsychological Investigations and Batteries

Agnosias: recognition disorders in patients with brain tumors

Introduction

Reconsidering outcomes that matter to patients